Physician profile
Michael Sigal
NPI 1215938774
$884.17
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $225 · 2021: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $211.50 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.24 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $158.47 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $101.86 | 2021 | |
| Aerie Pharmaceuticals, INC. | $66.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $66.07 | 2019 | |
| Alcon Vision LLC | $41.96 | 2019 | |
| Dompe US, INC. | $19.20 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.77 | 2019 | |
| Ivantis, INC | $14.09 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $13.54 | 2019 | |
| Biotissue Holdings INC. | $11.75 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sigal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.